Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0TGZKY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AMT-151
|
|||||
| Synonyms |
AMT151; AMT 151
Click to Show/Hide
|
|||||
| Organization |
Multitude Therapeutics, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 12 Indication(s)
Endometrial cancer [ICD11:2C76]
Phase 1
Endometrial clear cell carcinoma [ICD11:2C76]
Phase 1
Endometrial endometrioid adenocarcinoma [ICD11:2C76]
Phase 1
Epithelial ovarian cancer [ICD11:2B5D]
Phase 1
Lung cancer [ICD11:2C25]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Ovarian clear cell adenocarcinoma [ICD11:2C73]
Phase 1
Ovarian mucinous adenocarcinoma [ICD11:2C73]
Phase 1
Ovary endometrioid adenocarcinoma [ICD11:2C73]
Phase 1
Pleural mesothelioma [ICD11:2C26]
Phase 1
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Triple negative breast cancer [ICD11:2C60-2C65]
Phase 1
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Folate receptor alpha (FOLR1)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05498597 | Clinical Status | Phase 1 | ||
| Clinical Description | First-in-human, phase 1 study of AMT-151, an anti-folate receptor alpha antibody-drug conjugate, in patients with selected advanced solid tumours. | ||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.